|Videos|June 22, 2023
Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma
Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
5